About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.230 +0.010 (+0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities 
From USA News Group
Via GlobeNewswire
Friday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss ↗
Fate Therapeutics (NASDAQ:FATE) reported mixed Q2 2025 results, beating revenue estimates with $1.9M but posting a $0.29 loss per share. Progress in autoimmune and solid tumor therapies boosted... 
Via Chartmill
News headline image
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) 
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
4 Analysts Assess Fate Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications 
From Fate Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.